Atossa Therapeutics Inc (ATOS) - News Archive

Atossa Therapeutics Proposes Groundbreaking Clinical Study to Address Interval Breast Cancer in High-Risk Women: Insights from the AACR 2025 Meeting April 29, 2025 - In an exciting development for the future of breast c...

In a dynamic and often challenging landscape for biopharmaceutical innovation, Atossa Therapeutics, Inc. (Nasdaq: ATOS) continues to establish itself as a vanguard in the fight against breast cancer. The Seattle-based c...

Unlocking New Frontiers in Breast Cancer Treatment: Synergistic Therapies and Clinical Advances by Atossa TherapeuticsIn a significant stride toward innovative cancer treatment, Atossa Therapeutics, Inc. a clinical-stag...

Atossa Therapeutics has unveiled compelling data from its Phase 2 KARISMA-Endoxifen study, highlighting significant reductions in mammographic breast density among premenopausal women at risk of developing breast cancer...

Atossa Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on developing innovative therapies for oncology, has recently reported significant developments related to its lead candidate, (Z)-Endoxifen....

In a significant development for breast cancer awareness and early detection, the U.S. Food and Drug Administration (FDA) has implemented a final rule mandating patient notifications regarding breast density as part of...

Atossa Therapeutics, in collaboration with Quantum Leap Healthcare Collaborative, has initiated a groundbreaking clinical trial, the I-SPY 2 study, to evaluate the neoadjuvant potential of (Z)-endoxifen in combination w...

Breast cancer continues to be a significant global health concern, particularly among pre-menopausal women with Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer....

Atossa Therapeutics, a clinical-stage biopharmaceutical company focused on breast cancer treatment, has announced protocol changes for a clinical trial evaluating the combination of their proprietary drug, (Z)-endoxifen...

Atossa Therapeutics, Inc. Set to Join Russell 3000 Index: A Milestone for the Clinical Stage Biopharmaceutical Company Atossa Therapeutics, Inc. is making waves in the biopharmaceutical industry with its recent announce...

Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment ModelSeattle, May 28, 2024 - Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biophar...

Atossa Therapeutics Pioneers Pathway in Breast Cancer Therapy: A Synergistic Potential Unveiled SEATTLE, WA - Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company devoted to addressing si...

In a recent announcement, Atossa Therapeutics, a renowned clinical stage biopharmaceutical company focusing on breast cancer, has declared its endorsement of the newly released breast cancer screening guidelines by the...

In a groundbreaking move, Atossa Therapeutics, a clinical-stage biopharmaceutical company dedicated to addressing unmet medical needs in oncology, has announced an expanded research agreement with Weill Cornell Medicine...

Atossa Therapeutics, a clinical-stage biopharmaceutical company specializing in innovative oncology treatments, has partnered with Quantum Leap Healthcare Collaborative to launch a groundbreaking clinical study. This tr...

SEATTLE, April 09, 2024 - Atossa Therapeutics, a leading clinical stage biopharmaceutical company focused on breast cancer therapeutics, has unveiled encouraging results from its Phase 2 EVANGELINE clinical trial. The t...

The Impact and Success of Five-Year (Z)-Endoxifen Treatment in a Pre-Menopausal Breast Cancer Patient: A Testimony of Efficacy and Safety in ER+/HER2- Subtype Breast cancer remains a major health concern globally, with...

Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing RequirementsAtossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company, announced on March 18, 2024, that it has reg...

Data from Atossa s Phase 2 EVANGELINE Clinical Trial to be Presented at AACR Annual MeetingAtossa Therapeutics, Inc. is set to present data from the 40mg pharmacokinetic (PK) run-in cohort of its Phase 2 EVANGELINE stud...

Atossa Therapeutics, a leading clinical stage biopharmaceutical company focused on addressing unmet needs in oncology, recently announced a significant development in the ongoing RECAST DCIS study. The company disclosed...